http://orcid.org/0000-0002-6930-2862
References
- Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74:1216–1222.
- Ashizawa T, Xia G. Ataxia. Continuum (Minneap Minn). 2016;22:1208–1226.
- Bentea G, Sculier C, Grigoriu B, et al. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. Lung Cancer. 2017;106:83–92.
- Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27:489–495.
- Hahn AW, Gill DM, Agarwal N, et al. PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol. 2017;35:701–707.
- Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017;73:1–8.
- Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22:709–718.
- Gu Y, Menzies AM, Long GV, et al. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017;45:14–17.
- Seery V. Interprofessional collaboration with immune checkpoint inhibitor therapy: the roles of gastroenterology, endocrinology and neurology. Semin Oncol Nurs. 2017;33:402–414.